Actelion Will Launch Tracleer Through Closed Distribution System
Executive Summary
Actelion's launch of the pulmonary hypertension drug Tracleer will include converting 200 patients in an ongoing, open-label trial to its closed commercial distribution system, the company told analysts Nov. 21
You may also be interested in...
Viagra’s Second Wind: Pfizer Revatio Approved For Pulmonary Hypertension
Pfizer's post-marketing commitments for Revatio include submitting a plan to educate health care providers that the pulmonary arterial hypertension therapy has the same active ingredient as the erectile dysfunction drug Viagra
Viagra’s Second Wind: Pfizer Revatio Approved For Pulmonary Hypertension
Pfizer's post-marketing commitments for Revatio include submitting a plan to educate health care providers that the pulmonary arterial hypertension therapy has the same active ingredient as the erectile dysfunction drug Viagra
CoTherix Ventavis Clears FDA For Pulmonary Hypertension
CoTherix plans to improve the convenience and delivery of Ventavis shortly after the launch of the inhaled pulmonary arterial hypertension therapy